Biocept, Inc.
Index- P/E- EPS (ttm)-0.16 Insider Own0.04% Shs Outstand16.84M Perf Week-7.79%
Market Cap22.31M Forward P/E- EPS next Y-1.19 Insider Trans-7.11% Shs Float16.84M Perf Month-19.77%
Income-2.80M PEG- EPS next Q-0.14 Inst Own13.20% Short Float1.85% Perf Quarter-44.09%
Sales61.20M P/S0.36 EPS this Y87.30% Inst Trans-2.68% Short Ratio2.75 Perf Half Y-63.50%
Book/sh2.23 P/B0.64 EPS next Y-783.30% ROA-5.10% Target Price9.50 Perf Year-68.65%
Cash/sh1.84 P/C0.77 EPS next 5Y40.00% ROE-8.50% 52W Range1.43 - 4.97 Perf YTD-60.77%
Dividend- P/FCF10.62 EPS past 5Y79.90% ROI-6.30% 52W High-71.43% Beta0.66
Dividend %- Quick Ratio3.70 Sales past 5Y80.20% Gross Margin38.30% 52W Low-0.70% ATR0.12
Employees174 Current Ratio3.90 Sales Q/Q-24.30% Oper. Margin-3.80% RSI (14)31.75 Volatility9.20% 7.62%
OptionableYes Debt/Eq0.07 EPS Q/Q-168.50% Profit Margin-4.60% Rel Volume0.96 Prev Close1.54
ShortableYes LT Debt/Eq0.04 EarningsMar 31 AMC Payout- Avg Volume113.27K Price1.42
Recom2.00 SMA20-11.99% SMA50-24.82% SMA200-54.54% Volume109,121 Change-7.79%
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
May-16-22 04:05PM  
Apr-08-22 04:05PM  
Apr-06-22 08:00AM  
Mar-31-22 06:15PM  
Mar-18-22 08:00AM  
Mar-08-22 08:17AM  
Mar-04-22 08:00AM  
Feb-22-22 04:17PM  
Feb-18-22 04:54AM  
Feb-16-22 04:05PM  
Feb-10-22 08:17AM  
Jan-21-22 08:00AM  
Jan-07-22 09:40AM  
Jan-04-22 08:00AM  
Dec-09-21 08:17AM  
Dec-03-21 06:49AM  
Nov-22-21 01:56PM  
Nov-18-21 02:45PM  
Nov-15-21 04:05PM  
Nov-09-21 08:17AM  
Nov-08-21 08:00AM  
Oct-06-21 08:00AM  
Sep-29-21 01:28PM  
Sep-22-21 08:17AM  
Sep-21-21 08:17AM  
Sep-07-21 08:00AM  
Aug-31-21 08:00PM  
Aug-22-21 08:17AM  
Aug-19-21 11:37AM  
Aug-17-21 11:22AM  
Aug-16-21 04:05PM  
Aug-09-21 08:00AM  
Aug-03-21 08:17AM  
Jul-21-21 08:17AM  
Jul-20-21 08:17AM  
Jul-19-21 08:00AM  
Jul-06-21 08:27AM  
Jun-28-21 08:05AM  
Jun-22-21 08:17AM  
Jun-15-21 08:17AM  
Jun-09-21 08:37AM  
Jun-03-21 08:00AM  
Jun-02-21 04:05PM  
May-12-21 04:05PM  
May-05-21 08:00AM  
Apr-28-21 08:17AM  
Apr-21-21 08:17AM  
Apr-14-21 08:05AM  
Apr-07-21 04:05PM  
Apr-01-21 05:00PM  
Mar-30-21 08:06AM  
Mar-29-21 04:32PM  
Mar-27-21 04:18AM  
Mar-22-21 08:00AM  
Mar-16-21 11:41AM  
Mar-09-21 07:00AM  
Mar-03-21 04:05PM  
Mar-02-21 11:45AM  
Feb-23-21 12:35PM  
Feb-16-21 08:00AM  
Feb-03-21 08:00AM  
Feb-02-21 04:05PM  
Jan-23-21 02:03AM  
Jan-12-21 08:00AM  
Jan-04-21 08:05AM  
Dec-31-20 05:29PM  
Dec-30-20 08:05AM  
Dec-14-20 08:00AM  
Dec-10-20 08:00AM  
Dec-01-20 11:30AM  
Nov-20-20 08:00AM  
Nov-17-20 08:05AM  
Nov-16-20 06:47PM  
Nov-14-20 07:52AM  
Nov-12-20 04:05PM  
Nov-09-20 08:05AM  
Nov-05-20 08:05AM  
Nov-04-20 08:00AM  
Oct-29-20 08:05AM  
Oct-21-20 08:00AM  
Oct-06-20 08:00AM  
Oct-05-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:48AM  
Sep-23-20 08:00AM  
Sep-21-20 06:21PM  
Sep-16-20 08:00AM  
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HALE DAVID FDirectorDec 09Sale4.063741,519101Dec 10 05:04 PM
HALE DAVID FDirectorDec 09Sale4.0771289796Dec 10 05:04 PM